|77.60||+3.20||+4.30%||Vol 12.93M||1Y Perf 20.37%|
|Jun 4th, 2020 15:56 DELAYED|
|-0.30 -0.40%||-0.28 -0.36%|
|Target Price||82.11||Analyst Rating||Hold 2.57|
|Potential %||5.81||Finscreener Ranking||★+ 44.85|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★+ 54.81|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★ 52.50|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||★★★+ 52.08|
|Market Cap||97.34B||Earnings Rating||Strong Sell|
|Price Range Ratio 52W %||66.63||Earnings Date||30th Apr 2020|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||1.47|
|EPS Growth Next 5 Years %||3.50|
|Avg. Weekly Volume||16.01M|
|Avg. Monthly Volume||12.80M|
|Avg. Quarterly Volume||22.04M|
Gilead Sciences Inc. (NASDAQ: GILD) stock closed at 77.54 per share at the end of the most recent trading day (a 4.3% change compared to the prior day closing price) with a volume of 14.73M shares and market capitalization of 97.34B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 11000 people. Gilead Sciences Inc. CEO is Daniel OÂ¿Day.
The one-year performance of Gilead Sciences Inc. stock is 20.37%, while year-to-date (YTD) performance is 19.42%. GILD stock has a five-year performance of -31.39%. Its 52-week range is between 60.89 and 85.97, which gives GILD stock a 52-week price range ratio of 66.63%
Gilead Sciences Inc. currently has a PE ratio of 20.00, a price-to-book (PB) ratio of 4.42, a price-to-sale (PS) ratio of 4.15, a price to cashflow ratio of 11.00, a PEG ratio of 2.32, a ROA of 8.10%, a ROC of 11.99% and a ROE of 22.55%. The company’s profit margin is 21.72%, its EBITDA margin is 31.60%, and its revenue ttm is $22.72 Billion , which makes it $18.11 revenue per share.
Of the last four earnings reports from Gilead Sciences Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $1.47 for the next earnings report. Gilead Sciences Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Gilead Sciences Inc. is Hold (2.57), with a target price of $82.11, which is +5.81% compared to the current price. The earnings rating for Gilead Sciences Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Gilead Sciences Inc. has a dividend yield of 3.62% with a dividend per share of $2.72 and a payout ratio of 116.00%.
Gilead Sciences Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 9.91, ATR14 : 2.73, CCI20 : 35.40, Chaikin Money Flow : 0.07, MACD : -0.58, Money Flow Index : 57.16, ROC : 7.19, RSI : 53.43, STOCH (14,3) : 89.12, STOCH RSI : 0.96, UO : 60.15, Williams %R : -10.88), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Gilead Sciences Inc. in the last 12-months were: Andrew Dickinson (Option Excercise at a value of $0), Brett A. Pletcher (Option Excercise at a value of $4 204 162), Brett A. Pletcher (Sold 194 286 shares of value $13 104 895 ), Daniel O'Day (Option Excercise at a value of $0), Diane E. Wilfong (Option Excercise at a value of $762 211), Diane E. Wilfong (Sold 12 264 shares of value $982 220 ), Gayle E. Wilson (Option Excercise at a value of $426 364), Gayle E. Wilson (Sold 21 720 shares of value $1 470 878 ), Harish Manwani (Option Excercise at a value of $0), John F. Cogan (Option Excercise at a value of $426 364), John F. Cogan (Sold 21 720 shares of value $1 679 500 ), Kevin E. Lofton (Option Excercise at a value of $426 364), Per Wold-Olsen (Option Excercise at a value of $961 675), Per Wold-Olsen (Sold 46 910 shares of value $3 192 734 ), Richard J. Whitley (Option Excercise at a value of $0)
Copyright (c) 2020. All rights reserved. Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.com, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.